peptide 1 glp 1 Peptide-oligourea hybrids analogue of GLP-1 with improved action in vivo Current Insights, Advantages and Challenges

Why do GLP-1 medications need to be started at a low dose

Colom C, Rull A, Sanchez-Quesada JL, Prez A (2021) Cardiovascular disease in type 1 diabetes mellitus: epidemiology and management of cardiovascular risk

Traditional clinical trial designs typically focus on single disease entities, but a new paradigm is emerging

Daneshpour et al

Wellness IVs that a doctor actually approves

Both BPC-157 and TB-500 have been studied individually across tendon rupture, muscle tear, overuse injury, and joint damage models and the combined stack is used by researchers who want to address the inflammatory, cellular, and vascular dimensions of recovery at the same time